keyword
Keywords Cancer, Stem cell, Anemia, Pla...

Cancer, Stem cell, Anemia, Platelet, Thrombosis

https://read.qxmd.com/read/38093847/novel-combination-of-erythropoietin-and-romiplostim-to-treat-chemotherapy-induced-anemia-and-thrombocytopenia-via-pharmacodynamic-interaction-on-hematopoietic-stem-and-progenitor-cells
#1
JOURNAL ARTICLE
Xiaoqing Fan, Wojciech Krzyzanski, Raymond S M Wong, Dongyang Liu, Xiaoyu Yan
Chemotherapy-induced anemia and thrombocytopenia (CIAT) in cancer patients are often caused by the damage of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. We have previously shown that romiplostim, a thrombopoietin receptor agonist that could stimulate the expansion of HSPCs, could synergize with recombinant human erythropoietin (rHuEPO) to promote erythropoiesis in addition to stimulating platelet production, whereas rHuEPO could influence the platelet count through stem cell competition...
December 8, 2023: ACS Pharmacology & Translational Science
https://read.qxmd.com/read/36849497/mutations-in-the-alternative-complement-pathway-in-multiple-myeloma-patients-with-carfilzomib-induced-thrombotic-microangiopathy
#2
JOURNAL ARTICLE
Maria Moscvin, Christine Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Shahrier Hossain, Sean Rowell, Houry Leblebjian, Eileen Regan, Peter Czarnecki, Filippo Bagnoli, Niccolo' Bolli, Paul Richardson, Helmut G Rennke, Meletios A Dimopoulos, Efstathios Kastritis, Giada Bianchi
Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leading to microangiopathic hemolytic anemia, platelet consumption, fibrin deposition and small-vessel thrombosis with resultant tissue ischemia. The molecular mechanisms underlying carfilzomib-associated TMA are not known. Germline mutations in the complement alternative pathway have been recently shown to portend increased risk for the development of atypical hemolytic uremic syndrome (aHUS) and TMA in the setting of allogeneic stem cell transplant in pediatric patients...
February 27, 2023: Blood Cancer Journal
https://read.qxmd.com/read/36569714/heparin-induced-thrombocytopenia-at-the-emergency-department-due-to-intermittent-heparin-flush-in-a-patient-undergoing-stem-cell-transplant
#3
Kyaw Z Thein, Sarah A Elsaim, Maggie Q Ma, Cristhiam M Rojas Hernandez, Ahmed Elsayem
Heparin-induced thrombocytopenia (HIT) is an adverse reaction to heparin products, but not warfarin. HIT usually occurs 5‒10 days after exposure to heparin. Here, we report a case of HIT with multiple thrombotic events and severe thrombocytopenia resulting from intermittent intravenous heparin flushes for maintenance of a newly placed subclavian central venous catheter (CVC) for stem cell transplant. The patient is a woman in her forties with multiple myeloma who presented to the emergency department (ED) with dyspnea, pleuritic-type chest pain, hemoptysis, and worsening left-leg swelling...
November 2022: Curēus
https://read.qxmd.com/read/31531357/study-on-the-effect-of-ginsenosides-rb-on-blood-of-tumor-mice
#4
JOURNAL ARTICLE
Mengmeng Zheng, Wenxiu Zheng, Wei Wang, Hong Guo, Hui Cao, Xiaowei Cui, Shanshan Wang, Chunchao Han
Objective: The blood of cancer patients is in a state of hypercoagulability, easily leading to thrombosis. Anemia is also a complication of tumors. Anemia and thrombosis affect the treatment of tumor patients. Methods: Ginsenosides Rb were extracted from the stems and leaves of American ginseng using water-saturated ethanol and ethyl acetate in silica gel column. Tumor mice model was established by injecting H22 hepatocellular carcinoma cells into the axilla of mice...
2019: BioMed Research International
https://read.qxmd.com/read/18632152/myelofibrosis-with-myeloid-metaplasia-the-advanced-phase-of-an-untreated-disseminated-hematological-cancer-time-to-change-our-therapeutic-attitude-with-early-upfront-treatment
#5
REVIEW
Hans Carl Hasselbalch
Myelofibrosis with myeloid metaplasia (MMM) is the end stage of the Philadelphia-negative chronic myeloproliferative disorders, the classical clinical phenotype being featured by leukoerythroblastic anemia, bone marrow fibrosis and enlargement of the spleen and liver. In the early prefibrotic phase a proportion of the patients may be wrongly classified as having essential thrombocythemia (ET). Some patients with ET may also develop polycythemia vera (PV) and without a history of phlebotomies patients with primary myelofibrosis (PMF) are indistinguishable from those patients developing myelofibrosis during the course of polycythemia vera...
January 2009: Leukemia Research
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.